Biocryst Pharmaceuticals to Present New Clinical & Virologic Data for I.V. Peramivir at the 48th Annual Infectious Diseases Society of America Meeting
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.